Effects of One Year Treatment of Sibutramine on Insulin Resistance Parameters in Type 2 Diabetic Patients

Giuseppe Derosa¹, Pamela Maffioli¹, Ilaria Ferrari¹, Ilaria Palumbo¹, Sabrina Randazzo¹, Angela D’Angelo¹, Arrigo FG Cicero²

¹Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy
²“G. Descovich” Atherosclerosis Study Center, Department of Internal Medicine, Aging and Kidney diseases, University of Bologna, Bologna; Italy

Received, May 13, 2010; Revised, August 30, 2010; Accepted, September 9, 2010; Published, September 10, 2010

ABSTRACT – Purpose. comparison of the effects of one year treatment with sibutramine compared to placebo on insulin resistance parameters, body weight, glycemic control, and lipid profile, in type 2 diabetic patients. Methods. two hundred and forty-six patients with uncontrolled type 2 diabetes mellitus in therapy with different oral hypoglycemic agents or insulin were enrolled in this study and randomised to take sibutramine 10 mg or placebo for one year. We evaluated at baseline, and after 3, 6, 9, and 12 months these parameters: homeostasis model assessment insulin resistance index (HOMA-IR), retinol binding protein-4 (RBP-4), resistin, visfatin, and high sensitivity-C reactive protein (Hs-CRP), body weight, body mass index (BMI), glycated hemoglobin (HbA1c), fasting plasma glucose (FPG), post-prandial plasma glucose (PPG), fasting plasma insulin (FPI), total cholesterol (TC), low density lipoprotein-cholesterol (LDL-C), high density lipoprotein-cholesterol (HDL-C), and triglycerides (Tg). Results. a faster decrease of HOMA-IR, resistin, and RBP-4 was recorded with sibutramine compared to the control group. We observed a significant decrease of Hs-CRP in both groups, and a faster improvement of HbA1c, FPG and PPG with sibutramine compared to the control group; furthermore we recorded a decrease of FPI, TC, LDL-C, body weight, and BMI in the sibutramine group, but not in the control group. Conclusions. sibutramine gave a faster improvement of insulin resistance parameters and glycemic control compared to placebo; furthermore sibutramine gave also an improvement of lipid profile, and body weight.

INTRODUCTION

Overweight and obesity are increasing health problems associated with cardiovascular disorders and prematurity mortality (1). Weight loss is the recommended first step in managing cardiovascular risk (2). Intensive programs aimed at reducing calories (3) intake and at increasing physical activity (4) have clearly shown to improve the metabolic control of obese diabetic patients. However, the behavioural approach is usually slow and not always sufficient to get the optimal targets of weight and metabolic control in obese diabetic patients and a pharmacological treatment has often to be planned in order to significantly and quickly reduce their high cardiovascular disease risk (5). Weight loss drugs added to conventional lifestyle changes may help to achieve and maintain adequate weight loss and improve insulin sensitivity. Currently, two molecules are licensed for use as antiobesity drugs: orlistat, a gastrointestinal lipase inhibitor, reduces weight by around 3 kg on average, and sibutramine, a monoamine-reuptake inhibitor, results in mean weight losses of 4 to 5 kg (6). Sibutramine hydrochloride monohydrate is a norepinephrine and serotonin reuptake inhibitor approved for the long-term management of obesity, in conjunction with a reduced calorie diet and behaviour modification, in patients unable to lose weight with diet and lifestyle changes alone. Sibutramine is rapidly metabolized by the hepatic cytochrome P450 system (CYP) generating two pharmacologic active metabolites which affect both food intake and energy expenditure (7). The efficacy of sibutramine has been demonstrated in randomised trials in obese/overweight patients including those with type 2 diabetes mellitus (T2DM) (8-10). Furthermore, glycemic control was improved in randomised trials when sibutramine was added to diet and lifestyle advice for patients receiving conventional antidiabetic therapy (11). However preliminary data emerged from the SCOUT trial (12) showed that there was a 16% rise in the risk

Corresponding Author: Giuseppe Derosa, Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, P.le C. Golgi, 2 - 27100 PAVIA, Italy. E-mail: giuseppe.derosa@unipv.it.
of non-fatal myocardial infarction or stroke in people taking sibutramine and for this reason recently European regulators have suspended the marketing authorisation for sibutramine, and the US Food and Drug Administration has restricted its licence.

We conducted a study on sibutramine just before the withdrawal of sibutramine licence, evaluating sibutramine effects on different parameters; our primary endpoint was to evaluate sibutramine effect on insulin resistance parameters in type 2 diabetic patients, but we also evaluated body weight, glycemc and lipid profile, and the onset of adverse events.

METHODS

Study design

This multicenter, randomised, double-blind, controlled study was conducted in the Internal Medicine and Therapeutics Department at the University of Pavia (Pavia, Italy) and in the Internal Medicine, Aging and Kidney diseases Department “G. Descovich” Atherosclerosis Study Center, at the University of Bologna (Bologna, Italy).

The study protocol was approved at each site by institutional review boards and conducted in accordance with the Declaration of Helsinki and its amendments.

Patients

We enrolled 246 Caucasian type 2 diabetic patients aged ≥ 18 of either sex (Table 1) according to the ESC (European Society Cardiology) and EASD (European Association for the Study of Diabetes) Guidelines criteria (2), obese (body mass index [BMI] ≥ 30 kg/m²) (13), and with uncontrolled T2DM (glycated hemoglobin (HbA1c) > 8.0 %) in therapy with different oral hypoglycemic agents or insulin.

Suitable patients, identified from review of case notes and/or computerized clinic registers, were contacted by the investigators in person or by telephone.

Patients were excluded if they had a history of ketoacidosis or had unstable or rapidly progressive diabetic retinopathy, nephropathy, or neuropathy; impaired hepatic, or renal function, or severe anemia.

Table 1. General subjects characteristics at baseline in the study.

|                  | Control group | Sibutramine group |
|------------------|---------------|-------------------|
| N                | 121           | 125               |
| sex (M/F)        | 60/61         | 63/62             |
| age (years)      | 53 ± 6        | 51 ± 4            |
| Sex (M/F)        | 23/21         | 24/18             |
| Diab. dur. (years) | 4 ± 1       | 5 ± 2             |
| Weight (kg)      | 1.70 ± 0.05   | 1.71 ± 0.06       |
| Concomitant disease, n (%) | 108 (89.3) | 112 (89.6) |
| Hypertension     | 92 (85.2)     | 96 (85.7)         |
| Hypercholesterolemia | 36 (33.3) | 39 (34.8)         |
| Hypertriglyceridemia | 6 (5.5)    | 4 (3.6)           |
| Combined dyslipidemia | 28 (25.9) | 25 (22.3)         |
| Concurrent medications, n (%) | 109 (90.1) | 114 (91.2)  |
| ACE-I            | 28 (25.7)     | 30 (26.3)         |
| ARBs             | 36 (33.0)     | 31 (27.2)         |
| Calcium-antagonists | 19 (17.4) | 24 (21.0)         |
| β-blockers       | 7 (6.4)       | 9 (7.9)           |
| Diuretics        | 22 (20.2)     | 18 (15.8)         |
| Statins          | 44 (40.4)     | 48 (42.1)         |
| Fibrates         | 12 (11.0)     | 10 (8.8)          |
| Omega-3          | 10 (9.2)      | 14 (12.3)         |
| Acetylsalicylic acid | 99 (89.0) | 94 (82.5)         |
| Ticlopidine      | 10 (9.2)      | 7 (6.1)           |

Data are expressed as means ± SD or n and %
Sm. st.: Smoking status; Diab. dur.: diabetes duration; ACE-I: angiotensin-converting enzyme-inhibitors; ARBs: angiotensin receptor blockers
Patients with cardiovascular disease (CVD) (eg, New York Heart Association class I-IV congestive heart failure or a history of myocardial infarction or stroke) or past incidences of cerebrovascular conditions (stroke or TIA), history of coronary artery disease, congestive heart failure, tachycardia, peripheral arterial occlusive disease, arrhythmia were also excluded. Women who were pregnant or breastfeeding or who might become pregnant (due to inadequate contraceptive precautions). All patients provided written informed consent to participate.

At the beginning of the study and for all the observational period, patients were taking different antidiabetic drugs. The complete list of the antidiabetic drugs taken is reported in Table 2.

**Treatments**

Patients were divided in two groups and assigned to receive, as addition to their current antidiabetic therapy, either sibutramine 10 mg (sibutramine group) or placebo (control group) for 12 months in a randomised, double-blind, controlled study. Both placebo, and sibutramine were supplied as identical-looking, opaque, white capsules in coded bottles to ensure the blind status of the study. Randomisation was performed by drawing of envelopes containing randomisation codes prepared by a statistician. A copy of the code was provided only to the person responsible for performing the statistical analysis. The code was only broken after database lock, but it could have been broken for individual subjects in the event of an emergency. Medication compliance was assessed by counting the number of pills returned by patients at the time of their specified clinic visits. At baseline, we weighed participants and gave each patient a bottle containing a supply of study medication for at least 100 days. Throughout the study, we instructed patients to take their first dose of new medication on the day after they were given the study medication.

**Table 2. Antidiabetic agents before and during the study.**

|                          | Control group | Sibutramine group |
|--------------------------|---------------|-------------------|
| N                        | 121           | 125               |
| OHA, n (%)               | 118 (97.5)    | 116 (92.8)        |
| Sulphonylureas, n (%)    | 28 (22.7)     | 25 (21.5)         |
|  Gliburide               | 5 (17.9)      | 7 (28.0)          |
|  Glimepiride             | 17 (60.7)     | 14 (56.0)         |
|  Gliclazide              | 6 (21.4)      | 4 (16.0)          |
| Biguanides, n (%)        | 76 (64.4)     | 77 (66.4)         |
|  Metformin               | 76 (100.0)    | 77 (100.0)        |
|  Acarbose                | 17 (14.4)     | 20 (17.2)         |
|  Repaglinide             | 12 (70.6)     | 15 (75.0)         |
|  Nateglinide             | 5 (29.4)      | 5 (25.0)          |
| α-glucosidase inhibitors, n (%) | 19 (16.1) | 12 (10.3) |
|  Acarbose                | 19 (100.0)    | 12 (100.0)        |
|  4hydrodiones, n (%)     | 59 (50.0)     | 64 (55.2)         |
|  Pioglitazone            | 39 (66.1)     | 34 (53.1)         |
|  Rosiglitazone           | 20 (33.9)     | 30 (46.9)         |
| Incretin-mimetics, n (%) | 9 (7.6)       | 11 (9.5)          |
|  Exenatide               | 9 (100.0)     | 11 (100.0)        |
| DPP-4 inhibitors, n (%)  | 19 (16.1)     | 17 (14.6)         |
|  Sitagliptin             | 12 (63.2)     | 11 (64.7)         |
|  Vildagliptin            | 7 (36.8)      | 6 (35.3)          |
| INSULIN, n (%)           | 11 (9.1)      | 13 (10.4)         |
| Analogue, n (%)          | 9 (81.8)      | 9 (69.2)          |
|  Lispro                  | 6 (66.7)      | 7 (77.8)          |
|  Glulisine               | 3 (33.3)      | 2 (22.2)          |
|  Long-acting, n (%)      | 5 (45.4)      | 7 (53.8)          |
|  Lispro                  | 2 (40.0)      | 2 (28.6)          |
|  NPH                     | 3 (60.0)      | 5 (71.4)          |

Data are expressed as n or %

OHA: oral hypoglycemic agents; DPP-4: dipeptidyl peptidase-4 inhibitors; NPH: neutral protamine Hagedorn
A bottle containing placebo or the study medication for the next treatment period was given to participants each three months. At the same time, all unused medication was retrieved for inventory. Both placebo and medications were provided by each Hospital and were free of charge.

**Diet and Exercise**

Subjects began a controlled-energy diet (near 600 Kcal daily deficit) based on American Heart Association (AHA) recommendations (14) that included 50% of calories from carbohydrates, 30% from fat (6% saturated), and 20% from proteins, with a maximum cholesterol content of 300 mg/day and 35 g/day of fiber. Patients were not treated with vitamins or mineral preparations during the study.

Standard diet advice was given by a dietitian. Every three months a dietitian provided instruction on dietary intake recording procedures as part of a behaviour modification program and then later used the subject’s food diaries for counselling. Individuals were also encouraged to increase their physical activity by walking briskly for 20 to 30 minutes, 3 to 5 times per week, or by cycling. The recommended changes in physical activity throughout the study were assessed at each visit using the subject’s activity diary. Physical activity was evaluated using the Borg RPE Scale that measures perceived exertion (15).

**Assessments**

Before starting the study, all patients underwent an initial screening assessment that included a medical history, physical examination, vital signs, and a 12-lead electrocardiogram. Blood pressure, and vital sign measurements were assessed twice week for the first 12 weeks of treatment, and if there was a rise of > 10 mmHg, or heart rate > 10 bpm or weight loss > 2 kg after 4 weeks treatment patients were discontinued from the study. We evaluated at baseline, and after 3, 6, 9, and 12 months these parameters: homeostasis model assessment insulin resistance index (HOMA-IR), retinol binding protein-4 (RBP-4), resistin, visfatin, and high sensitivity-C reactive protein (HS-CRP), body weight, BMI, HbA1c, fasting plasma glucose (FPG), post-prandial plasma glucose (PPG), fasting plasma insulin (FPI), total cholesterol (TC), low density lipoprotein-cholesterol (LDL-C), high density lipoprotein-cholesterol (HDL-C), and triglycerides (TG).

In order to evaluate the tolerability assessments, all adverse events were recorded. All plasmatic parameters were determined after a 12-h overnight fast, with the exception of PPG, determined 2 hours after a standardized meal. Venous blood samples were taken for all patients between 08.00 and 09.00. We used plasma obtained by addition of Na2-EDTA, 1 mg/ml, and centrifuged at 3000 g for 15 minutes at 4°C. Immediately after centrifugation, the plasma samples were frozen and stored at -80°C for no more than 3 months. All measurements were performed in a central laboratory.

The HOMA-IR index was calculated as the product of basal glucose (mmol/l) and insulin levels (μU/ml) divided by 22.5 (16-17).

Retinol binding protein-4 was measured using a retinol binding protein-4 (Human) EIA kit (Phoenix Pharmaceuticals, Inc., Burlingame, CA, USA). The intra- and interassay Cv were less than 5.0% and less than 14.0%, respectively (18).

Resistin value was measured by a commercially available enzyme-linked immunosorbent assay (ELISA) kit (BioVendor Laboratorites Medicine, Brno, Czech Republic). Intra-assay Cv was 3.4% and inter-assay Cv was 6.9%, respectively (19).

Visfatin levels were measured by enzyme immunoassay (EIA) kit obtained from Phoenix Pharmaceuticals, Inc., (Burlingame, CA, USA). The intra- and interassay Cv were 5.7% and less than 14%, respectively (20).

High sensitivity C-reactive protein was measured with use of latex-enhanced immunonephelometric assays on a BN II analyser (Dade Behring, Newark, Delaware, USA). The intra- and interassay Cv were 5.7% and 1.3%, respectively (21).

Body mass index was calculated as weight in kilograms divided by the square of height in meters. Glycated hemoglobin level was measured by an HPLC method (DIAMAT, Bio-Rad, USA; normal values 4.2-6.2%), with intra- and interassay Cv of < 2% (22). Plasma glucose was assayed by glucose-oxidase method (GOD/PAP, Roche Diagnostics, Mannheim, Germany) with intra- and interassay Cv of < 2% (23). Plasma insulin was assayed with Phadiaseph Insulin RIA (Pharmacia, Uppsala, Sweden) by using a second antibody to separate the free and antibody-bound 125 I-insulin (intra- and interassay coefficients of variation: 4.6 and 7.3%, respectively) (24).

Total cholesterol and Tg levels were determined using fully enzymatic techniques (25-
on a clinical chemistry analyzer (HITACHI 737; Hitachi, Tokyo, Japan); intra- and interassay CsV were 1.0 and 2.1 for TC measurement, and 0.9 and 2.4 for Tg measurement, respectively. High density lipoprotein-cholesterol level was measured after precipitation of plasma apo B-containing lipoproteins with phosphotungstic acid (27) intra- and interassay CsV were 1.0 and 1.9, respectively; LDL-C level was calculated by the Friedewald formula (28).

**Statistical Analysis**

An intention-to-treat analysis was conducted in patients who had received ≥ 1 dose of study medication and had a subsequent efficacy observation. Patients were included in the tolerability analysis if they had received ≥ 1 dose of trial medication and had undergone a subsequent tolerability observation. Considering as clinically significant a difference of at least the 10% compared to the baseline and an alpha error of 0.05, the actual sample size was adequate to obtain a power higher than 0.80 for all measured variable. Continuous variables were compared by analysis of variance (ANOVA). Intervention effects were adjusted for additional potential confounders using analysis of covariance (ANCOVA). ANOVA was also used to assess the significance within and between groups. The statistical significance of the independent effects of treatments on the other variables was determined using ANCOVA. 1-sample t test was used to compare values obtained before and after treatment administration; 2-sample t tests were used for between group comparisons (29). Statistical analysis of data was performed using the Statistical Package for Social Sciences software version 11.0 (SPSS Inc., Chicago, Illinois, USA). Data are presented as mean ± standard deviation (SD). For all statistical analyses, p < 0.05 was considered statistically significant.

**RESULTS**

**Study sample**

A total of 246 type 2 diabetic patients were enrolled in the study; of these, 24 patients did not complete the study and the reasons for premature withdrawal are explained in Figure 1. The characteristics of the patient population at study entry are shown in Table 1.
246 patients randomised

125 patients randomised to sibutramine
121 patients randomised to placebo

15 patients lost to follow-up:
- 2 males and 2 females for headache
- 2 males for constipation
- 2 females and 1 male for insomnia
- 1 male for dry mouth
- 2 females for increased blood pressure
- 1 female and 1 male for increased heart rate
- 1 female for malaise

9 patients lost to follow-up:
- 3 males for headache
- 1 female for constipation
- 1 female for insomnia
- 1 male for dry mouth
- 1 female for increased blood pressure
- 1 male for malaise
- 1 female for palpitation

110 patients completed the study in sibutramine group
112 patients completed the study in control group

222 patients completed the study

**Figure 1.** Study design
Glycemic parameters

We observed a statistically significant improvement of HbA1c after 9 and 12 months (p < 0.05, and p < 0.01, respectively) compared to baseline in the control group and after 6, 9, and 12 months in the sibutramine group (p < 0.05, p < 0.01, and p < 0.001, respectively). We did not record any significant differences between the two groups (Table 3).

There was a statistically significant decrease of FPG after 12 months (p < 0.05) compared to baseline in the control group and after 9, and 12 months in the sibutramine group (p < 0.05, and p < 0.01 respectively). No differences between the two groups were recorded (Table 3).

A significant decrease of PPG was reported after 12 months (p < 0.05) compared to baseline in the control group and after 9, and 12 months in the sibutramine group (p < 0.05, and p < 0.01 respectively). No differences between the two groups were obtained (Table 3).

There was a decrease of FPI after 12 months (p < 0.05) compared to baseline in the group treated with sibutramine not observed in the control group, even if we did not record any differences between the two groups (Table 4, and Figure 2).

Lipid profile

A significant decrease of TC, and LDL-C was observed after 12 months (p < 0.05, for both) with sibutramine, but not in the control group, while we did not observe any variations of Tg, or HDL-C neither in the control group nor in the sibutramine group. We did not obtain any significant differences between the two groups (Table 3).

Correlations

Stepwise multilinear regression analysis was undertaken to establish which anthropometric and metabolic factors could best predict the insulin-resistance (HOMA) improvement changes or which metabolic factors could best predict the anthropometric (BMI) improvement change. Significant predictors of change in insulin-resistance (HOMA) were RBP-4 and resistin concentration in sibutramine group (r = 0.58, p < 0.01, and r = 0.64, p < 0.01, respectively).

DISCUSSION

We have already demonstrated in two our previous studies that sibutramine appears to be a tolerable and efficacious drug when added to pioglitazone for the global management of obese diabetic patients (30-31). Sibutramine appeared to give a better improvement of body weight compared to pioglitazone, while both drugs equally reduced blood pressures, improved glycemic control and HOMA index. Both pioglitazone and sibutramine gave a TC, LDL-C, and Tg decrease, while no HDL-C variations were observed (30).

In the current study we have recorded that both placebo and sibutramine added to the usual antidiabetic therapy taken before the beginning of the study, gave a similar improvement of glycemic control, even if sibutramine addition gave a faster improvement of glycemic parameters. We have also observed that sibutramine, but not placebo, gave an improvement of lipid profile, even if, at the end of the study, no significant differences between the two groups were observed. Furthermore we confirmed that sibutramine gave an improvement of body weight, according to what previously reported by our group (30).

Regarding insulin resistance, it has been reported in literature that in T2DM patients the HOMA-IR resulted to be increased compared to the normal glucose tolerance (NGT) subjects (32) and that exercise training can improve insulin sensibility (33). Data from our study showed that sibutramine gave a faster improvement of FPI and HOMA-IR compared to placebo, confirming what already reported in literature (29-30).

Compared to our previous studies, we have also evaluated some insulin resistance parameters, such as RBP-4, resistin, and visfatin. Regarding RBP-4, its concentration has been reported to be increased in subjects with obesity, insulin resistance or T2DM compared with lean subjects (34), even if the mechanisms by which RBP-4 induces insulin resistance are not well understood. On the other side, resistin is produced by mononuclear cells and activated macrophages: it has been demonstrated that overexpression of resistin decreases the ability of insulin to suppress hepatic glucose output or increase glucose uptake by muscle (35-37).
### Available data support also a role of resistin in determining an increase of inflammation and atherosclerosis (38). In our study we observed that sibutramine, added to the previously taken antidiabetic therapy, gave an improvement of RBP-4, and resistin faster than placebo, improving insulin resistance and glucose intolerance. It has been already reported that insulin resistance and hyperglycemia often co-exist with a cluster of risk factors for coronary artery disease and cardiomyopathy and that the over-production of free radicals in patients suffering from diabetes results in a state of oxidative stress, which leads to endothelial dysfunction and a greater risk of atherosclerosis (39). Reducing insulin resistance we obtain also an improvement of risk of cardiovascular events.

We have also analysed visfatin: visfatin was discovered as a secretory protein highly enriched in human visceral adipocytes, yet this protein is also expressed by liver, muscle, bone marrow and lymphocytes, where it was first identified as PBEF (pre-B-cell colony stimulating factor) (40-41). The expression and secretion of visfatin is increased during the development of obesity; however, in contrast with inflammatory cytokines, the rise in visfatin does not decrease insulin sensitivity. Instead, visfatin exerts insulin-mimetic effects in cultured adipocytes, hepatocytes and myotubes and lowers plasma glucose in mice (40). Visfatin binds to the insulin receptor with similar affinity but at a site distinct from insulin (40). In contrast with insulin, visfatin levels do not change with feeding and fasting (40). It remains to be determined if visfatin acts in concert with insulin to regulate metabolism and whether such interaction occurs via endocrine or paracrine mechanisms. In our study neither placebo nor sibutramine improved visfatin levels.

### Table 3. Body weight, glycemic profile, and lipid profile data during the study.

|                        | Sibutramine group            | Control group               |
|------------------------|-------------------------------|-----------------------------|
|                        | Baseline | 3 month | 6 month | 9 month | 12 month | Baseline | 3 month | 6 month | 9 month | 12 month |
| Weight (Kg)            | 97.7±11.4 | 96.5±10.7 | 94.2±9.2 | 90.4±7.1* | 88.6±6.0** | 95.0±9.6 | 91.3±8.5 | 91.0±8.2 | 90.5±7.3 | 89.9±6.5 |
| BMI (Kg/m²)            | 33.4±3.2 | 33.0±3.0 | 32.2±2.7 | 30.9±2.1* | 30.3±1.9** | 32.8±3.1 | 31.6±2.5 | 31.5±2.4 | 31.3±2.3 | 31.1±2.2 |
| HbA1c (%)              | 8.7±1.5  | 8.4±1.3  | 7.8±1.0*  | 7.5±0.8** | 7.3±0.6  | 8.6±1.4  | 8.4±1.3  | 8.1±1.2  | 8.1±1.0*  | 7.5±0.8** |
| FPG (mg/dL)            | 144±20  | 135±15  | 128±12  | 124±10*  | 120±9**  | 141±18  | 139±17  | 135±13  | 126±11*  | 126±11*  |
| PPG (mg/dL)            | 185±29  | 174±24  | 169±22  | 165±20*  | 161±21** | 182±27  | 178±25  | 175±23  | 166±21*  | 166±21*  |
| TC (mg/dL)             | 224±28  | 218±23  | 211±21  | 206±17  | 197±15*  | 219±24  | 211±22  | 214±22  | 208±18  | 210±20  |
| LDL-C (mg/dL)          | 160±15  | 156±13  | 147±9  | 138±6*  | 15±12  | 146±9  | 148±10 | 145±8  | 148±10 |
| HDL-C (mg/dL)          | 43±7    | 42±6    | 43±7    | 44±7    | 41±6  | 45±8  | 47±9  | 47±9  | 44±8  | 44±8  |
| Tg (mg/dL)             | 105±42  | 99±40  | 107±44  | 101±40  | 91±36  | 97±39  | 93±36  | 95±37  | 91±35  | 90±32  |

Data are means ± SD

*p< 0.05 vs baseline; **p< 0.01 vs baseline; ^p< 0.001 vs baseline

*<p< 0.05 vs Control group; ;<p< 0.01 vs Control group

BMI: body mass index; HbA1c: glycated hemoglobin; FPG: fasting plasma glucose; PPG: post-prandial plasma glucose; TC: total cholesterol; LDL-C: low density lipoprotein-cholesterol; HDL-C: high density lipoprotein-cholesterol; Tg: triglycerides
Regarding inflammatory parameters, Hs-CRP has been shown to independently predict myocardial infarction, stroke, and peripheral artery disease (42-43). In our study both sibutramine and placebo improved this parameter.

Regarding adverse reactions we did not observe any significant differences between the group treated with sibutramine, and the group treated with placebo; the reported adverse effects were headache, constipation, insomnia, dry mouth, increased blood pressure, increased heart rate, depression, malaise, palpitation. All the events were reported as mild or moderate. This was in line with what already reported by our group in two previous studies (44-45); sibutramine intake was not associated to any cardiovascular effects and was generally well tolerated.

This was in contrast with what recently reported by unpublished data from the sibutramine cardiovascular outcomes trial (SCOUT) (12). This six year trial of 10000 mostly European patients, which began in December 2002, showed a 16% rise in the risk of non-fatal myocardial infarction or stroke in people taking sibutramine. We think that the reason of these differences between our results in adverse effects and SCOUT results is that patients enrolled in the SCOUT trial had a history of cardiovascular disease and diabetes, and that 90% of these patients would not have been eligible for sibutramine under the current label.

The controversy between our study and the SCOUT trial is similar to the one reported on the clinical use of sulfonylurea, tolbutamide, on cardiovascular disease reported in 1970 by University Group Diabetes Programme (UGDP) (46).

|                     | Sibutramine group | Control group |
|---------------------|-------------------|---------------|
|                     | Baseline | 3 month | 6 month | 9 month | 12 month | Baseline | 3 month | 6 month | 9 month | 12 month |
| n                   | 125      | 119     | 116     | 112     | 110      | 121      | 117      | 115      | 114      | 112      |
| sex (M/F)           | 63/62    | 61/58   | 59/57   | 58/54   | 56/54    | 60/61    | 59/58    | 57/57    | 57/57    | 55/57    |
| Sm. st. (M/F)       | 24/18    | 22/18   | 21/18   | 21/17   | 21/17    | 23/21    | 22/21    | 21/21    | 21/21    | 20/21    |
| FPI (μU/mL)         | 24.9±7.2 | 24.0±6.8 | 23.3±5.9 | 22.4±5.4 | 21.2±5.0* | 23.7±6.1 | 23.4±6.1 | 23.1±5.6 | 22.8±5.6 | 22.5±5.5 |
| HOMA-IR             | 8.9±5.1  | 8.0±4.5 | 7.4±4.1 | 6.9±3.6* | 6.3±3.5** | 8.3±4.7  | 8.1±4.6  | 7.8±4.4  | 7.4±4.1  | 7.1±3.8* |
| RBP-4 (μg/mL)       | 43.9±11.8 | 41.4±10.2 | 37.6±9.4 | 36.4±9.0* | 35.0±8.6* | 41.6±10.3 | 30.2±10.1 | 38.7±9.6 | 37.1±9.1 | 35.8±8.9* |
| Resistin (ng/mL)    | 7.1±2.5  | 6.9±2.3 | 6.4±1.9 | 6.0±1.7* | 5.5±1.5** | 6.9±2.3  | 6.8±2.2  | 6.5±2.0  | 6.4±1.9  | 6.2±1.8* |
| Visfatin (ng/mL)    | 17.9±6.5 | 16.9±6.0 | 16.6±5.8 | 16.5±5.7 | 16.3±5.7 | 17.8±6.4  | 17.3±6.1 | 17.5±6.2 | 16.9±6.0 | 16.7±5.9 |
| Hs-CRP (mg/L)       | 2.6±1.8  | 2.2±1.4 | 2.1±1.3 | 1.7±1.0 | 1.7±1.0 | 2.4±1.6  | 2.3±1.5  | 2.2±1.4  | 2.1±1.3  | 1.9±1.2* |

Data are means ± SD
* p<0.05 vs baseline; ** p<0.02 vs baseline; *** p<0.01 vs baseline

FPI: fasting plasma insulin; HOMA-IR: homeostasis model assessment insulin resistance index; RBP-4: retinol binding protein-4; Hs-CRP: high sensitivity-C reactive protein.
Figure 2. Inflammatory and insulin resistance parameters variations during the study *p< 0.05 vs baseline; $p< 0.02 vs baseline; **p< 0.01 vs baseline HOMA-IR: homeostasis model assessment insulin resistance index; FPI: fasting plasma insulin; RBP-4: retinol binding protein-4; Hs-CRP: high sensitivity-C reactive protein.

The study found cardiovascular disease mortality was higher in patients given tolbutamide than those given insulin (12.7% vs 6.2%). These findings remained in controversy as United Kingdom Prospective Study (UKDPS 33 & 34) (47) showed reduction in cardiovascular effects of sulfonylureas.

Of course our study has some limitations: for example we did not evaluate if the beneficial effects on glycemic control, body weight, lipid
profile and insulin resistance parameters were sustained after the cessation of therapy. Another limitation is that we evaluated only a limited number of insulin resistance biomarkers, more parameters should be considered to evaluated an effective improvement of insulin resistance.

However, at the best of our knowledge, this is the first study investigating the effect of sibutramine on insulin resistance and inflammatory parameters.

CONCLUSIONS

All data considered we can safely conclude that sibutramine gave a faster improvement of glycemic control and of insulin resistance parameters compared to placebo. Sibutramine gave also an improvement of lipid profile, and body weight not observed with placebo.

AKNOWLEDGEMENTS

The authors certify that have no affiliation with, or financial involvement in, any organization or entity with a direct financial interest in the subject matter or materials discussed in the manuscript.

REFERENCES

1. Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature 2006; 444: 77-80.

2. Ryden L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, De Boer MJ, Costabile F, Jonsson B, Laaksonen M, Malmberg K, Priori S, Ostergren J, Qumilen J, Thabebiott I, Vanhorebeek I, Vrba-McCue L, Lindgren P, Qiao Q, Priori S, Blanc J, Stajdel A, Camm J, Dean V, Deckers J, Doshi K, Lekakis J, McGregor K, Metra M, Mora A, Osterspey A, Tamargo J, Zamora J, Decker JW, Bertrand M, Charbonnel B, Ehrmann E, Ferrannini E, Flyvbjerg A, Gohilke H, Juanatey JR, Graham I, Monteiro PF, Parhofer K, Pyoráll K, Raz I, Scherthanner G, Volpe M, Wood D; Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC); European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007; 28: 88-136.

3. American Diabetes Association. Physical Activity/Exercise and Diabetes. Diabetes Care 2004; 27: 58-62.

4. Lee M, Aronne LJ. Weight management for type 2 diabetes mellitus: global cardiovascular risk reduction. Am J Cardiol 2007; 99: 68B-79B.

5. Bolen S, Feldman L, Vassy J, Wilson L, Yeh HC, Marinopoulos S, Wiley C, Selvin E, Wilson R, Bass EB, Brancati FL. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 2007; 147: 386-399.

6. Padwal RS, Majumdar SR. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet 2007; 369: 71-77.

7. Arterburn DE, Crane PK, Veenstra DL. Efficacy and safety of sibutramine for weight loss: a systematic review. Arch Intern Med 2004; 164: 994-1003.

8. James WP, Astrup A, Burcel H, Copeland J, Kopelman P, Rössner S, Saris WH, Van Gaal LF. Effect of sibutramine on weight maintenance after weight loss: A randomized trial. STORM Study Group. Sibutramine Trial of Obesity: Reduction and Maintenance. Lancet 2000; 356: 2119-2125.

9. Wadden TA, Berkowitz RI, Womble LG, Santer D, Phelan S, Cato RK, Lessen LA, Osei SY, Karp J, Stunkard AJ. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med 2005; 353: 2111-2120.

10. Finer N, Bloom SR, Frost GS, Banks LM, Egli J. Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study. Diabetes Obes Metab 2000; 2: 105-112.

11. Finer N, Ryan DH, Renz CL, Hewkin AC. Prediction of response to sibutramine therapy in obese non-diabetic and diabetic patients. Diabetes Obes Metab 2006; 8: 206-213.

12. Caterson I, Coutinho W, Finer N, Van Gaal L, Maggioni A, Torp-Pedersen C, Sharma AM, Ge H, Santoro D, Shepherd G, James P; SCOUT Investigators. Early response to sibutramine in patients not meeting current label criteria: preliminary analysis of SCOUT lead-in period. Obesity 2010; 18: 987-994.

13. World Health Organization. Obesity: preventing and managing the global epidemic. Report of WHO consultation on obesity. Geneva: WHO; 1997.

14. Lichtenstein AH, Appel LJ, Brands M, Carnethon M, Daniels S, Franch HA, Franklin B, Kris-Etherton P, Harris WS, Howard B, Karanja N, Leferve M, Rudel L, Sacks F, Van Horn L, Winston M, Wylie-Rosett J. Summary of American Heart Association Diet and Lifestyle Recommendations Revision 2006. Arterioscler Thromb Vasc Biol 2006; 26: 2186-2191.

15. Borg G. Perceived exertion as an indicator of somatic stress. Scand J Rehabil Med 1970; 2: 92-98.
16. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.

17. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004; 27: 1487-1495.

18. Takebayashi K, Suetsumu M, Wakabayashi S, Aso Y, Inumai T. Retinol binding protein-4 and clinical features of type 2 diabetes patients. J Clin Endocrinol Metab 2007; 92: 2712-2719.

19. Yannakoulia M, Yannakouris N, Bluhm S, Matalas AL, Klimis-Zacas D, Mantzoros CS. Body fat mass and macronutrient intake in relation to circulating soluble leptin receptor, free leptin index, adiponectin, and resistin concentrations in healthy humans. J Clin Endocrinol Metab 2003; 88: 1730-1736.

20. Korner A, Garten A, Bluher M, Tauscher R, Kiehl J, Kiss W. Molecular characteristics of serum visfatin and differential detection by immunoassays. J Clin Endocrinol Metab 2007; 92: 4783-4791.

21. Rifai N, Tracy RP, Ridker PM. Clinical Efficacy of an Automated High-Sensitivity C-Reactive Protein Assay. Clin Chem 1999; 45(12): 2136-2141.

22. Bunn HF, Gabbay KH, Gallop PM. The glycosylation of haemoglobin: Relevance to diabetes mellitus. Science 1978; 199: 1243-1245.

23. European Diabetes Policy Group. A guide to type 2 diabetes mellitus. Diabet Med 1999; 16(6): 716-730.

24. Heding LG. Determination of the total serum immunoreactive insulin (IRI) in insulin-treated diabetic patients. Diabetes 1972; 21: 1-5.

25. Klose H, Böker K. Enzymatische Bestimmung des Gesamtcholesterins mit dem Greiner Selective Analyzer (GSA II). J Clin Chem Clin Biochem 1972; 15: 90-93.

26. Havel RJ, Edr HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1955; 34: 1345-1353.

27. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.

28. Winer BJ. Statistical Principles in Experimental Design. 2nd ed, McGraw-Hill, New York, 1971.

29. Derosa G, D’Angelo A, Salvadeo SAT, Ferrari I, Gravina A, Fogari E, Maffioli P, Cicero AFG. Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone. Metabolism 2008; 57: 1552-1557.

30. Derosa G, Moreu R, Salvadeo SAT, D’Angelo A, Ciccarelli L, Piccinni MN, Ferrari I, Gravina A, Maffioli P, Cicero AFG. Pioglitazone metabolic effect in metformin-intolerant obese patients treated with sibutramine. Inter Med 2009; 48: 265-271.

31. Li YB, Zhu DL, Tian HM, Shi LX, Luo ZJ, Yan L, Zeng LY, Zhou ZG, Yang LY, Liu J, Li M, Weng JP. Characteristics of dysfunction of islet beta-cell in newly diagnosed type 2 diabetic patients. Zhonghua Yi Xue Za Zhi 2006; 86: 2537-2541.

32. Qiu S, Wu C, Lin F, Chen L, Huang Z, Jing L. Exercise training improved insulin sensitivity and ovarian morphology in rats with polycystic ovary syndrome. Horm Metab Res 2006; 38: 805-808.

33. Cho YM, Youn BS, Lee H, Lee N, Min SS, Kwak SH, Lee HK, Park KS. Plasma homocysteine and homocysteine-thiolactone concentrations are elevated in human subjects with impaired glucose tolerance and type 2 diabetes. Diabetes Care 2006; 29: 245-249.

34. Stepan CM, Bailey SA, Bhat S, Brown EJ, Bjerregje RR, Wright CM, Bfrall HR, Ahima RS, Lever MA. The hormone resistin links obesity to diabetes. Nature (London) 2001; 409: 307-312.

35. Satoh H, Nguyen HT, Miles PD, Imamura T, Usui I and Sho Y. Adenovirus-mediated chronic ‘hyper-resistinemia’ leads to in vivo insulin resistance in normal rats. J Clin Invest 2004; 114: 224-231.

36. Rangwala SM, Rich AS, Rhoades B, Shapiro JS, Obici S, Rossetti L, Lazar MA. Abnormal glucose homeostasis due to chronic hyperresistinemia. Diabetes 2004; 53: 1937-1941.

37. Reilly MP, Lehrke M, Wolfe M, Rohatgi A, Lazar MA, Rader DJ. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 2005; 111: 932-939.

38. Sharma AK, Srinivasan BP. Triple versus glimepiride plus metformin therapy on cardiovascular risk biomarkers and diabetic cardiomyopathy in insulin resistance type 2 diabetes mellitus rats. Eur J Pharm Sci 2009; 38: 433-444.

39. Fukushima K, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsu Y, Murakami M, Ichisaka T, Murakami H, Watanabe E, Takagi T, Akiyoshi M, Ohtsubo T, Kihara S, Yamashita S, Sakai M, Funahashi T, Yama Y, Hiramatsu R, Matsuzawa Y, Shimomura I, Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005; 307: 426-430.

40. Hug C, Lodish HF. Visfatin: a new adipokine. Science 2005; 307: 366-367.

41. Zwacka TP, Hornbach Y, Torzewski J. C-reactive protein-mediated lipoprotein uptake by macrophages. Circulation 2001; 103: 1194-1197.
43. Andersen K, Pedersen BK. The role of inflammation in vascular insulin resistance with focus on IL-6. Horm Metab Res 2008; 40: 635-639.

44. Derosa G, Cicero AFG, Murdolo G, Piccinni MN, Fogari E, Bertone G, Ciccarelli L, Fogari R. Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients. Diabetes Obes Metab 2005; 7: 47-55.

45. Derosa G, Cicero AF, Murdolo G, Ciccarelli L, Fogari R. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients. Diabetes Nutr Metab 2004; 17: 222-229.

46. Pogátsa G. What kind of cardiovascular alterations could be influenced positively by oral antidiabetic agents? Diabetes Res Clin Pract 1996; 31: S27-S31.

47. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes. N Engl J Med 2008; 359 (15): 1577-1589.